EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Did Nirsevimab Shift Pediatric Hospitalizations Due to Lower Respiratory Tract Infections? A Nationwide Italian Study (2024–2025)

Paolo Manzoni iD, Matteo Riccò iD, Chryssoula Tzialla iD, Graziano Barera, Paolo Del Barba, Simona De Franco, Guido Pellegrini, Enrico Crapanzano, Giangiacomo Nicolini iD, Andrea Alba, Stefano Fiocchi, Mauro Vivalda und 21 weitere

Viruses · 24.02.2026 · 18 (3) · 274

DOI: 10.3390/v18030274 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Viruses, online erschienen am 24.02.2026. Verfasst von Paolo Manzoni und 32 weiteren Autor:innen. Beteiligte Einrichtung: SCDU Pediatria e Neonatologia Ospedale Degli Infermi, ASL Biella, 13875 Ponderano, Italy. Hauptthemen laut MEDLINE: Hospitalization, Respiratory Tract Infections, Respiratory Syncytial Virus Infections, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nirsevimab is a long-acting monoclonal antibody designed to prevent infections due to respiratory syncytial virus (RSV). Here we report on a retrospective, multicenter study encompassing a total of 19 Italian neonatal and pediatric centers evaluating the epidemiology of lower respiratory tract infection (LRTI)-related hospitalizations in infants younger than 2 years during the first RSV season following the introduction of nirsevimab prophylaxis. A total of 401 hospitalizations were reported, with 40.4% being in children with previous prophylaxis with nirsevimab. Respiratory syncytial virus was the most frequently identified pathogen (47.5%), followed by rhinovirus/enterovirus (20.2%) and human metapneumovirus (hMPV; 6.9%). In multivariable analyses adjusted for age, sex, and month of diagnosis, prior nirsevimab immunization was associated with a significantly reduced likelihood of RSV-related hospitalization (adjusted odds ratio [aOR], 0.259; 95% CI, 0.157–0.427), corresponding to an estimated effectiveness of 74.1% (95% CI, 57.3–84.3). Conversely, nirsevimab-immunized infants showed increased odds of hospitalization due to hMPV (aOR, 2.490; 95% CI, 1.019–6.085) and rhinovirus/enterovirus (aOR, 2.573; 95% CI, 1.424–4.650). Lower respiratory tract infections associated with hMPV predominantly occurred outside the typical RSV season, being associated with moderate-to-severe clinical presentations. These findings confirm the real-world effectiveness of nirsevimab against RSV hospitalizations, also highlighting the need for the continued surveillance of non-RSV respiratory pathogens in the context of universal RSV immunoprophylaxis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HospitalizationRespiratory Tract InfectionsRespiratory Syncytial Virus InfectionsAntibodies, Monoclonal, HumanizedAntiviral AgentsHumansItalyRetrospective StudiesInfantMaleFemaleMetapneumovirusInfant, NewbornRespiratory Syncytial Virus, Human

Stichwörter der Autor:innen

human metapneumoviruslower respiratory tract infectionsmonoclonal antibodiesrespiratory infectionsrespiratory syncytial virusrespiratory virus

Substanzen

Antibodies, Monoclonal, HumanizedAntiviral Agents

Autor:innen und Institutionen

  • SCDU Pediatria e Neonatologia Ospedale Degli Infermi, ASL Biella, 13875 Ponderano, Italy.
  • Postgraduate School of Pediatrics, University of Turin, 10124 Turin, Italy.
  • Servizio di Prevenzione e Sicurezza Negli Ambienti di Lavoro (SPSAL), AUSL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.
  • SC Pediatria e Nido, ASST Pavia-Ospedale Civile di Voghera, 27058 Voghera, Italy.
  • SC Patologia Neonatale, ASST Papa Giovanni XXIII, 24127 Bergamo, Italy.
  • U.O. Pediatria e U.O. Patologia Neonatale, Dipartimento Materno Infantile, IRCCS Ospedale San Raffaele, 20132 Milan, Italy.

ORCID-Profile: Paolo Manzoni, Matteo Riccò, Chryssoula Tzialla, Giangiacomo Nicolini, Mariano Manzionna, Luca Pierri, Claudio Costantino, Cecilia Nobili, Mario Giuffrè

Zitieren

APA

Manzoni, P., Riccò, M., Tzialla, C., Barera, G., Barba, P. D., De Franco, S., Pellegrini, G., Crapanzano, E., Nicolini, G., Alba, A., Fiocchi, S., Vivalda, M., Natta, G., Casati, A., Manzionna, M., Rugolotto, S., Saggioro, L., Pesce, S., Scavone, M., …, & Giuffrè, M. (2026). Did Nirsevimab Shift Pediatric Hospitalizations Due to Lower Respiratory Tract Infections? A Nationwide Italian Study (2024–2025). Viruses, 18(3), 274. https://doi.org/10.3390/v18030274

Vancouver

Manzoni P, Riccò M, Tzialla C, Barera G, Barba PD, De Franco S, et al. Did Nirsevimab Shift Pediatric Hospitalizations Due to Lower Respiratory Tract Infections? A Nationwide Italian Study (2024–2025). Viruses. 2026;18(3):274. doi:10.3390/v18030274

BibTeX
@article{Manzoni2026,
  author = {Manzoni, Paolo and Riccò, Matteo and Tzialla, Chryssoula and Barera, Graziano and Barba, Paolo Del and De Franco, Simona and Pellegrini, Guido and Crapanzano, Enrico and Nicolini, Giangiacomo and Alba, Andrea and Fiocchi, Stefano and Vivalda, Mauro and Natta, Giulia and Casati, Alessandra and Manzionna, Mariano and Rugolotto, Simone and Saggioro, Laura and Pesce, Simona and Scavone, Maria and Distilo, Antonietta and Roseto, Vincenza and Di Toro, Antonino and Pierri, Luca and Scarpelli, Gianfranco and Bonanno, Elvira and Decembrino, Lidia and Felici, Enrico and Selvatico, Camilla and Saracco, Valentina and Morrone, Francesco and Costantino, Claudio and Nobili, Cecilia and Giuffrè, Mario},
  title = {Did Nirsevimab Shift Pediatric Hospitalizations Due to Lower Respiratory Tract Infections? A Nationwide Italian Study (2024–2025)},
  journal = {Viruses},
  year = {2026},
  volume = {18},
  number = {3},
  pages = {274},
  doi = {10.3390/v18030274}
}
Kostenlos starten →